Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Ventricular Dysfunction 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypertension 1Essential Hypertension 1Cardiotoxicity 1Barrett Esophagus 1

Interventions

relacorilant 5Nutrition Assessment 4Hydrochlorothiazide 3Amlodipine 3aliskiren 2Osilodrostat 2Lisinopril 2Bevacizumab 2Adrenalectomy 2sacubitril and valsartan sodium hydrate drug combination 1pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1ganirelix 1gallium Ga 68 dotatate 1fimasartan 1enzalutamide 1clevidipine 1cediranib 1bicalutamide 1benazepril 1Vitamin D 1Tumor Necrosis Factors 1Thiazides 1Therapeutics 1Surveys and Questionnaires 1Sulindac 1Sodium Chloride 1Resistance Training 1Receptors, Androgen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypertension × Enalapril × Clear all
NCT01151410 2016-03-07

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Novartis

Phase 3 Completed
208 enrolled 10 charts

Essential Hypertension, Hypertension, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡